Nano-Sized Liposomes for Click-Chemistry-Based Selective Guiding of Immune Cells to Neuroblastoma
Source abstract
Abstract
Neuroblastoma is a prevalent extracranial solid tumor that mainly affects children, for which current therapies often cause significant side effects due to limited specificity. To address this, nanomedicine has introduced engineered nanocarriers for targeted drug delivery, yet challenges such as poor tumor perfusion and immune clearance remain. Herein, we present an approach using bifunctional nanosized liposomes to enhance immune cell targeting of neuroblastoma cells through click chemistry. These liposomes, functionalized with azide or strained alkyne groups and targeting moieties, were designed to selectively label macrophages and neuroblastoma cells, facilitating their recognition through bio-orthogonal chemical reactions. In vitro studies under physiological flow conditions demonstrated the successful labeling of both cell types and subsequent interaction, mimicking the in vivo environment. This strategy could change the current paradigm of cell-based treatments for solid tumors like neuroblastoma, owing to an improvement in the immune cell targeting efficacy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics · Virus-based gene therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Dpto. Materiales y Producción Aeroespacial, ETSI Aeronáutica y del Espacio
Universidad Politécnica de Madrid
Advanced Optical Microscopy unit, Instituto de salud Carlos III (ISCIII)
Servicio de Hematología y Oncología Pediátrica
Hospital Infantil Universitario Niño Jesús
Funding
Asociaci?n Pablo Ugarte · Ministerio de Ciencia, Tecnolog?a e Innovaci?n
References (54)
Show source-provided references
1. 10.1016/j.neuron.2022.07.01210.1016/j.neuron.2022.07.012 ↗
2. 10.3390/children509011410.3390/children5090114 ↗
3. 10.1002/jcp.2997910.1002/jcp.29979 ↗
4. 10.1016/j.addr.2018.07.00710.1016/j.addr.2018.07.007 ↗
5. 10.1016/j.jconrel.2022.03.04310.1016/j.jconrel.2022.03.043 ↗
6. 10.7150/thno.4957710.7150/thno.49577 ↗
7. 10.3390/jpm1108077110.3390/jpm11080771 ↗
8. 10.34133/bmef.001610.34133/bmef.0016 ↗
9. 10.1186/s13045-022-01320-510.1186/s13045-022-01320-5 ↗
10. 10.1016/j.biomaterials.2015.07.05410.1016/j.biomaterials.2015.07.054 ↗
11. 10.1039/C6NR07532K10.1039/C6NR07532K ↗
12. 10.1002/anie.20181169110.1002/anie.201811691 ↗
13. 10.1016/j.addr.2022.11423810.1016/j.addr.2022.114238 ↗
14. 10.1016/j.addr.2021.11408310.1016/j.addr.2021.114083 ↗
15. 10.1038/s41573-020-0064-x10.1038/s41573-020-0064-x ↗
16. 10.1016/j.addr.2022.11430010.1016/j.addr.2022.114300 ↗
17. 10.1002/adma.20200205410.1002/adma.202002054 ↗
18. 10.1056/NEJMra170616910.1056/NEJMra1706169 ↗
19. 10.1038/s41408-021-00459-710.1038/s41408-021-00459-7 ↗
20. 10.1016/j.phrs.2021.10603610.1016/j.phrs.2021.106036 ↗
21. 10.1016/j.bcp.2020.11435410.1016/j.bcp.2020.114354 ↗
22. 10.1038/s41565-020-00822-y10.1038/s41565-020-00822-y ↗
23. 10.1038/s41375-021-01127-210.1038/s41375-021-01127-2 ↗
24. 10.1002/adma.20210719210.1002/adma.202107192 ↗
25. 10.1021/acs.chemrev.0c0092810.1021/acs.chemrev.0c00928 ↗
26. 10.1021/ja044996f10.1021/ja044996f ↗
27. 10.1016/j.bbcan.2022.18880510.1016/j.bbcan.2022.188805 ↗
28. 10.3390/cancers1208205710.3390/cancers12082057 ↗
29. 10.3390/cancers1210291210.3390/cancers12102912 ↗
30. 10.3390/ijms2004084010.3390/ijms20040840 ↗
31. 10.1021/acs.bioconjchem.9b0045610.1021/acs.bioconjchem.9b00456 ↗
32. 10.1021/acs.nanolett.8b0356810.1021/acs.nanolett.8b03568 ↗
33. 10.1039/C5TB00287G10.1039/C5TB00287G ↗
34. 10.1039/D4BM00780H10.1039/D4BM00780H ↗
35. 10.1016/S0022-2836(65)80093-610.1016/S0022-2836(65)80093-6 ↗
36. 10.1016/j.biomaterials.2019.11961510.1016/j.biomaterials.2019.119615 ↗
37. 10.7150/thno.4244510.7150/thno.42445 ↗
38. 10.1021/acs.nanolett.4c0171110.1021/acs.nanolett.4c01711 ↗
39. 10.1002/anie.20120670310.1002/anie.201206703 ↗
40. 10.3390/ph1608115510.3390/ph16081155 ↗
41. 10.1039/D0SC03477K10.1039/D0SC03477K ↗
42. 10.1016/j.jconrel.2019.12.02310.1016/j.jconrel.2019.12.023 ↗
43. 10.1016/j.addr.2020.07.00210.1016/j.addr.2020.07.002 ↗
44. 10.1073/pnas.230356712010.1073/pnas.2303567120 ↗
45. 10.1021/acsami.6b0131510.1021/acsami.6b01315 ↗
46. 10.1002/cnma.20160004710.1002/cnma.201600047 ↗
47. 10.1002/mabi.20220016710.1002/mabi.202200167 ↗
48. 10.1002/mabi.20220016710.1002/mabi.202200167 ↗
49. 10.3390/pharmaceutics1410207610.3390/pharmaceutics14102076 ↗
50. 10.1136/jitc-2021-00240810.1136/jitc-2021-002408 ↗
51. 10.3390/vaccines1101005510.3390/vaccines11010055 ↗
52. 10.1021/acs.accounts.9b0014810.1021/acs.accounts.9b00148 ↗
53. 10.1016/j.bioactmat.2020.12.01010.1016/j.bioactmat.2020.12.010 ↗
54. 10.1038/s41590-023-01687-810.1038/s41590-023-01687-8 ↗